Curated News
By: NewsRamp Editorial Staff
May 19, 2026

CEL-SCI Raises $7.2M in Public Offering to Advance Multikine

Discuss on Substack
Original Source

TLDR

  • CEL-SCI raised $7.2M to advance Multikine, potentially offering a first-mover advantage in neoadjuvant head and neck cancer therapy.
  • CEL-SCI closed a public offering of 6 million shares at $1.20 each, netting $7.2M for Multikine development and general corporate uses.
  • Multikine aims to boost patients' immune systems before standard treatments, potentially improving survival and quality of life for cancer patients.
  • Multikine is given before surgery to harness the immune system, a unique approach that has already been tested in over 740 patients.

Impact - Why it Matters

This funding is crucial for CEL-SCI as it advances Multikine, a potential neoadjuvant therapy for head and neck cancer. If successful, Multikine could offer a novel treatment approach that primes the immune system before standard treatments, potentially improving survival rates for patients with squamous cell carcinoma. The capital raise demonstrates investor confidence and provides the resources needed to move toward clinical milestones, which could ultimately impact the standard of care in oncology.

Summary

CEL-SCI Corporation (NYSE American: CVM) has successfully closed a best-efforts public offering, issuing 6 million shares of common stock at $1.20 per share. The offering generated gross proceeds of approximately $7.2 million before fees and expenses. The company intends to use the net proceeds to support the continued development of its lead candidate, Multikine, as well as for general corporate purposes and working capital. This financial boost comes as CEL-SCI advances its immunotherapy approach, which aims to harness the patient's immune system before it is compromised by surgery, radiotherapy, or chemotherapy.

Multikine (Leukocyte Interleukin, Injection) is designed to be administered right after diagnosis and before surgery, targeting the tumor when the immune system is still relatively intact. The therapy has been dosed in over 740 patients and has received Orphan Drug designation from the FDA for neoadjuvant therapy in patients with squamous cell carcinoma of the head and neck. CEL-SCI, with operations in Vienna, Virginia, and near Baltimore, Maryland, believes that this timing maximizes the immune system's ability to attack the tumor, potentially improving survival outcomes.

The announcement was disseminated via InvestorWire, a specialized communications platform within the Dynamic Brand Portfolio @ IBN. InvestorWire provides advanced wire-grade press release syndication, editorial syndication to 5,000+ outlets, and social media distribution through IBN, ensuring broad reach and impact for corporate communications. For more details, the full press release can be accessed at https://ibn.fm/T5Ng2.

Source Statement

This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, CEL-SCI Raises $7.2M in Public Offering to Advance Multikine

blockchain registration record for this content.